The Tempus AI, Inc. (NASDAQ: TEM) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Tempus is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, and its filings offer insight into how it reports financial performance, manages capital, and documents material corporate events.
Investors can review Form 8-K filings where Tempus discloses items such as preliminary financial results, earnings press releases, credit agreement amendments, securities offerings, and other significant developments. For example, Tempus has used 8-K reports to furnish quarterly financial information, describe an automatic shelf registration statement and related prospectus supplement, and detail the terms of its convertible senior notes due 2030, including conversion features, redemption provisions, and associated capped call transactions.
Over time, this page will also surface Tempus’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically include segment information for its Diagnostics and Data and applications businesses, risk factor discussions, and management’s analysis of operations. In addition, users can expect access to ownership and insider transaction disclosures, such as Form 4 filings, when they are available from EDGAR.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings in clear language. Real-time updates from EDGAR help ensure that new TEM filings appear promptly, while AI-generated highlights can draw attention to important terms in credit agreements, securities offerings, or covenant changes. This combination allows readers to navigate Tempus’s regulatory history more efficiently, from capital structure details to ongoing financial reporting.
Vanessa Kubo has filed to sell 20,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with a stated aggregate market value of $922,400.00. The shares relate to Restricted Stock Awards originally dated October 14, 2015.
The filing also lists recent sales under a Rule 10b5-1 trading plan: 23,818 shares of common stock for $1,100,036.71 on August 3, 2026, 33,284 shares for $1,910,172.09 on July 8, 2026, and 10,000 shares for $600,000.00 on July 6, 2026.
Tempus AI, Inc. director David R. Epstein sold 370 shares of Class A Common Stock on 2026-08-03 at $43.40 per share. The sale was executed under a Rule 10b5-1 trading plan adopted on August 27, 2024, leaving him holding 31,094 shares directly.
Tempus AI, Inc. executive Ryan Fukushima, CEO, Data, reported that his spouse sold 23,818 shares of Class A Common Stock on August 3, 2026, in multiple transactions at weighted-average prices between $43.25 and $46.94 under a Rule 10b5-1 trading plan adopted on March 12, 2026. After these sales, Fukushima continues to hold 603,558 shares directly.
TEM has a shareholder preparing to sell common stock pursuant to a notice of proposed sale. The filing lists 990 common shares to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services at 1 New York Plaza, New York, with an indicated value of 43431.30 and NASDAQ as the trading market as of 08/03/2026.
The securities derive from Restricted Stock Units from the issuer dated 08/01/2026. The disclosure also notes earlier 10b5‑1 plan sales by David Epstein, including a sale of 250 common shares on 06/01/2026 for 12350.00 within the prior three months.
TEM insider Vanessa Kubo filed a notice to sell up to 23,818 shares of common stock, held through Morgan Stanley Smith Barney LLC Executive Financial Services. These shares originate from Restricted Stock Awards dated 10/14/2015 issued by the company. The filing also lists recent 10b5-1 plan sales, including 33,284 common shares on 07/08/2026 for $1,910,172.09 and 10,000 shares on 07/06/2026 for $600,000.00.
Polovin Andrew reported acquisition or exercise transactions in this Form 4 filing.
Tempus AI, Inc. reported that EVP and Chief Legal Officer Andrew Polovin received a grant of 40,000 restricted stock units (RSUs) of Class A Common Stock on July 29, 2026 at $0.0000 per share. The RSUs vest in eight equal quarterly installments commencing on October 29, 2026, and his direct holdings after the grant are 168,215 shares.
Rogers James William reported acquisition or exercise transactions in this Form 4 filing.
Tempus AI, Inc. reported that Chief Financial Officer James William Rogers received a grant of 40,000 restricted stock units ("RSUs") representing Class A Common Stock on July 29, 2026. The RSUs vest in eight equal quarterly installments commencing on October 29, 2026 and increase his direct holdings to 154,866 shares.
Tempus AI, Inc. CEO and Chairman Eric P. Lefkofsky reported that entities he manages or for which he serves as trustee sold an aggregate 250,000 shares of Class A Common Stock on July 28, 2026, at weighted-average prices reflecting trades between $40.79 and $43.13 per share, pursuant to a Rule 10b5-1 trading plan adopted March 8, 2026.
After these transactions, Lefkofsky continues to hold substantial positions, including 2,230,721 shares directly and significant indirect holdings such as 5,715,203 shares through the Lefkofsky Family 2025 GRAT and 4,284,797 shares through the Lefkofsky Family 2026 GRAT.
Tempus AI, Inc. reported Q2 2026 total net revenue of $382,486, up from $314,635 a year earlier. Diagnostics revenue was $289,333 and Data and applications revenue $93,153. Despite a loss from operations of $75,913, net income reached $5,642, supported by $102,757 of other income, including gains on marketable equity securities.
For the first half of 2026, revenue was $730,602, while the company recorded a net loss of $120,277 and used $80,802 of cash in operating activities. Cash, cash equivalents and restricted cash totaled $604,338 at June 30, 2026, and marketable equity securities were $216,377; the company believes these resources can fund its current operating plan for at least one year.
Tempus reshaped its capital structure, issuing $460,000 of 0.00% convertible senior notes due 2032 and previously $750,000 of 0.75% notes due 2030, while repaying long-term debt and a $100,000 revolving credit facility. Convertible senior notes, net, rose to $1,172,781, stock-based compensation reached $106,827 for the first half, and accumulated deficit increased to $2,516,139.
Tempus AI reported second quarter 2026 results with revenue of $382.5 million, up 22% year-over-year for the quarter ended June 30, 2026. Diagnostics generated $289.3 million of revenue (20% growth) and Data and Applications produced $93.2 million (28% growth), driving gross profit to $246.5 million, a 26% increase. Management described the quarter as exceptional, citing strong Oncology Diagnostics and Data Licensing performance.
The company recorded net income of $5.6 million, compared with a net loss of $(42.8 million) in Q2 2025, and Adjusted EBITDA of $8.0 million versus $(5.6 million) a year earlier. Cash and marketable securities totaled $820.7 million as of June 30, 2026, and Tempus completed a $460 million 0.0% convertible senior notes offering due 2032. Tempus agreed to acquire Personalis for $16.25 per share (~$1.5 billion enterprise value) and raised full-year 2026 revenue guidance to $1.595–$1.605 billion, expecting full-year Adjusted EBITDA of about $65 million, excluding any impact from the Personalis transaction.